Psychoactive Research chemicals are new synthetic substances that are structurally similar to the original drug, while being functional analogs. Research on the effects of, and treatment for, abuse of these drugs is limited due to the fact that they’re fairly new and have avoided mainstream notice. Research chemicals do not have a lot of human consumption data, and thus harm-reduction and special care should be taken if choosing to ingest them.

Psychedelics are drugs which cause profound changes in a one’s perceptions of reality, otherwise known as hallucinations. While under the influence of hallucinogens, users might see images, hear sounds or feel sensations. These chemicals offer some of the most intense psychological experiences and care should be taken when ingesting them.

This is a commonly used substance with well known and widely available human consumption data. This does not guarantee that the substance will be safe. The safety profile has been established based on usage data commonly available.

Disclaimer: Psychedelic drugs offer some of the most power and intense psychological experiences. Additionally these substances are illegal in many places. We understand that even though these substances are illegal, their use occurs frequently. We do not condone breaking of the law. By providing accurate information about these substances, we encourage the user to make responsible decisions and practice harm reduction.

Read the full disclaimer here.

Practice Harm Reduction. Proceed with Caution.



Also known as:

  • 1H-Indole-3-ethanamine, 5-methoxy-N-methyl-N-(1-methylethyl)-[ACD/Index Name]
  • 5-Methoxy-N,N-methylisopropyltryptamine
  • 5-Methoxy-N-methyl-N-isopropyltryptamine
  • 5-Methoxy-N-Methyl-N-Isopropyltryptamine(5-MeO-MIPT)
  • N-[2-(5-Methoxy-1H-indol-3-yl)ethyl]-N-methyl-2-propanamin[German][ACD/IUPAC Name]
  • N-[2-(5-Methoxy-1H-indol-3-yl)ethyl]-N-methyl-2-propanamine[ACD/IUPAC Name]
  • N-[2-(5-Méthoxy-1H-indol-3-yl)éthyl]-N-méthyl-2-propanamine[French][ACD/IUPAC Name]
  • N-[2-(5-Methoxy-1H-indol-3-yl)ethyl]-N-methylpropan-2-amine
  • [2-(5-methoxyindol-3-yl)ethyl]methyl(methylethyl)amine
  • 1H-Indole-3-ethanamine,5-methoxy-N-methyl-N-(1-methylethyl)-
  • 3-[(2-Aminoethyl)-N-isopropyl-N-methyl]-5-methoxyindole
  • 5-MEO-MIPT
  • 5-MeO-NIPT
  • 5-methoxy MiPT
  • 5-Methoxy-3-[2-[methyl(isopropyl)amino]ethyl]-1H-indole
  • 5-Methoxy-N-isopropyl-N-methyltryptamine
  • 5-Methoxy-N-methyl,N-isopropyl tryptamine
  • 5-methoxy-N-methyl-N-(1-methylethyl)-1H-Indole-3-ethanamine
  • 5-Methoxy-N-methyl-N-isopropyl Tryptamine
  • I-7975
  • Isopropyl-[2-(5-methoxy-1H-indol-3-yl)-ethyl]-methyl-amine
  • MFCD04972085[MDL number]
  • MFCD07437975[MDL number]
  • N-(2-(5-Methoxy-1H-indol-3-yl)ethyl)-N-methylpropan-2-amine
  • N-2-(5-methoxy-1H-indole-3-yl)ethyl-N-methylpropan-2-amine[ACD/IUPAC Name]
  • N-Isopropyl-N-methyl-5-methoxytryptamine, free base

A potent, stimulating psychedelic tryptamine, sometimes compared to 5-MeO-DiPT. Has an unusually strong body component and weak visual effects. Often said to be very empathogenic.


5-MeO-MiPT is chemically related to tryptamines like 5-MeO-DMT and 5-MeO-DiPT. It produces its psychoactive effects through activity at serotonin receptors in the brain. The synthesis and pharmacology of 5-MeO-MiPT was first reported in 1985 by David Repke and Alexander Shulgin.

Its effects in humans was documented in Shulgin’s book TiHKAL (“Tryptamines I Have Known and Loved”). Anecdotal reports describe 5-MeO-MiPT’s effects as highly stimulating and mildly entactogenic, lacking in typical psychedelic visual distortions. Many users report strong physical and tactile effects that serve to enhance libido and sexual pleasure.

An unpleasant “body load” is also often reported at common to high doses, marked by muscle tension and nausea. Very little is known about the pharmacological properties, metabolism and toxicity of 5-MeO-MiPT, and it has a limited history of human use. It has been sold online as a research chemical.

It is highly advised to use harm reduction practices when using this substance.





Tryptamines share a core structure comprised of a bicylic indole heterocycle attached at R3 to an amino group via an ethyl side chain.

5-MeO-MiPT is substituted at R5 of its indole heterocycle with a methoxy (MeO) functional group CH3O−; it also contains a methyl group and an isopropyl chain bound to the terminal amine RN of its tryptamine backbone (MiPT). 5-MeO-MiPT is the N-substituted isopropyl homologue of 5-MeO-DMT.

Common Name5-Methoxy-N,N-methylisopropyltryptamine
Systematic name5-Methoxy-N,N-methylisopropyltryptamine
Std. InChiInChI=1S/C15H22N2O/c1-11(2)17(3)8-7-12-10-16-15-6-5-13(18-4)9-14(12)15/h5-6,9-11,16H,7-8H2,1-4H3
Avg. Mass246.348 Da
Molecular Weight246.348
Monoisotopic Mass246.173218 Da
Nominal Mass246
ChemSpider ID2043845

Subscribe for the latest updates

Dosing Guide



5-MeO-MiPT Duration Data
Onset30 minutes
Duration3-7 hours
After-effects2-10 hours

Interactions and Synergies

There are no existing interaction or synergy data for this drug.

General Information

Come up
EffectsEuphoria, empathy, insight, brightened colour, Closed/Open eye visuals, enhanced tactile sensation, mental/physical stimulation, decreased appetite, pupil dilation, restlessness, change in perception, ego softening, sweating/chills, muscle tension, confusion, insomnia.
After Effects
Test Kits
Marguis Test Result
Note 2:
Note 3:


Pharmacological Effects

5-MeO-MiPT’s psychedelic effects are believed to come from its efficacy at the 5-HT2A receptor as a partial agonist and additional mechanisms of action such as the inhibition of MAO (i.e. digestive enzymes in the stomach) have also been speculated upon, though this has yet to be demonstrated scientifically.

Subjective Effects

5-MeO-MiPT can be taken via oral ingestion or it can be smoked. When ingested orally, the visual and sensory effects are reported to become more prominent. The experience can be broken up into two stages; the first half feels stimulating and entactogenic whilst the second half feels more similar to a traditional tryptamine psychedelic like psilocybin mushrooms or LSD. When smoked, the physically and cognitively stimulating effects become emphasized.

Physical Effects

  • Stimulation - At doses below 10 to 15mg, 5-MeO-MiPT produces a degree of stimulation comparable to that of LSD.
  • Spontaneous bodily sensations - The "body high" of 5-MeO-MiPT can be described as a pleasurable, warm, soft and all-encompassing glow. This may be accompanied by a cold, sharp tingling sensation that manifests spontaneously at different unpredictable points throughout the experience, although for others can maintain a consistent presence that steadily rises with the onset and hits its limit once the peak has been reached.
  • Nausea - Nausea is commonly reported and can sometimes result in vomiting, although it typically fades after the come up phase. In comparison to 5-MeO-DiPT, this substance has a much lower tendency to trigger unpleasant physical reactions.
  • Bodily pressures
  • Abnormal heartbeat
  • Increased heart rate
  • Increased blood pressure
  • Headaches
  • Dehydration
  • Stomach bloating - At higher doses, this compound can induce severe stomach bloating within those who are susceptible. This can be partially to fully mitigated through the use of antacids.
  • Pupil dilation
  • Vasoconstriction
  • Diarrhea

Psychological Effects

At low to moderate doses, the cognitive effects of 5-MeO-MiPT are often described by many as both insightful and moderately relaxing, but at some points quite stimulating. 5-MeO-MiPT produces a large number of typical psychedelic cognitive effects which progressively intensify proportional to dosage. At higher dosages, however, it becomes primarily sedating and impairing with depersonalization and no accompanying insight.

Visual Effects




The visual geometry produced by 5-MeO-MiPT can be described as more similar in appearance to that of Psilocin, 4-AcO-DMT or ayahuasca than that of LSD or 2C-B. It can be comprehensively described through its variations as intricate in complexity, abstract in form, organic in feel, brightly lit, multicoloured in scheme, glossy in shading, equal in blurred and sharp edges, large in size, fast in speed, smooth in motion, equal in rounded and angular corners, non-immersive in depth and progressive in intensity. At higher dosages they are significantly more likely to result in states of level 8B visual geometry over level 8A.

Hallucinatory states

5-MeO-MiPT produces a full range of high level hallucinatory states in a fashion that is more consistent and reproducible than that of many other commonly used psychedelics.

Auditory Effects

Sensory Effects

Transpersonal Effects

Legal Status

  • Brazil: 5-MeO-MiPT is illegal to produce, sell, or possess as it is listed on Portaria SVS/MS nº 344.
  • China: 5-MeO-MiPT is controlled as a Category I psychotropic substance and is illegal to sell, buy, import, export, and manufacture.
  • Finland: 5-MeO-MiPT was banned in Finland in December 2014.
  • Germany: 5-MeO-MiPT is controlled under the NpSG (New Psychoactive Substances Act) as of July 18, 2019. Production and import with the aim to place it on the market, administration to another person and trading is punishable. Possession is illegal but not penalized.
  • Japan: 5-MeO-MiPT is controlled as a "Designated Substance" (Shitei-Yakubutsu) by the Pharmaceutical Affairs Law, making it illegal to possess or sell.
  • Latvia: 5-MeO-MiPT is a Schedule I drug in Latvia.
  • New Zealand: 5-MeO-MiPT is an analogue of DMT which makes it a Class C controlled drug in New Zealand.
  • Romania: 5-MeO-MiPT and other derivatives are illegal in Romania, as of January 2011.
  • United Kingdom: 5-MeO-MiPT is a Class A drug in the UK as it is an ether of the drug 5-HO-MiPT, which is a Class A drug as a result of the tryptamine catch-all clause.
  • United States: 5-MeO-MiPT is unscheduled in the United States. It may be considered an analogue of 5-MeO-DiPT, a Schedule I drug under the Controlled Substances Act. As such, the sale for human consumption or the use for illicit non-medical or industrial intents and purposes could be prosecuted as crimes under the Federal Analogue Act.
    • Florida: 5-MeO-MiPT is a Schedule I drug in Florida.
    • Louisiana: 5-MeO-MiPT is a Schedule I drug (as of June 2013).
    • Minnesota: Minnesota banned a series of drugs including 5-MeO-MiPT.

  • References

    1. Repke, D. B., Grotjahn, D. B., & Shulgin, A. T. (1985). Psychotomimetic N-methyl-N-isopropyltryptamines. Effects of variation of aromatic oxygen substituents. Journal of medicinal chemistry, 28(7), 892-896. PMID: 4009612
    2. http://isomerdesign.com/PiHKAL/read.php?domain=tk&id=40
    3. The effects of non-medically used psychoactive drugs on monoamine neurotransmission in rat brain (ScienceDirect) | http://www.sciencedirect.com/science/article/pii/S0014299906013811
    4. Psychotomimetic N-methyl-N-isopropyltryptamines. Effects of variation of aromatic oxygen substituents | http://pubs.acs.org/doi/abs/10.1021/jm00145a007
    5. The effects of non-medically used psychoactive drugs on monoamine neurotransmission in rat brain. (PubMed.gov / NCBI) | https://www.ncbi.nlm.nih.gov/pubmed/17223101
    6. Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity | http://bja.oxfordjournals.org/content/95/4/434
    7. http://portal.anvisa.gov.br/documents/10181/3115436/(1)RDC_130_2016_.pdf/fc7ea407-3ff5-4fc1-bcfe-2f37504d28b7
    8. Erowid China Psychoactive Law Update: September 2015 | https://www.erowid.org/psychoactives/law/countries/china/china_law_2015_09_27_list_of_newly_controlled_chemicals.pdf
    9. Finland's Prohibited Psychoactive Substances: December 19, 2014. https://www.erowid.org/psychoactives/law/countries/finland/finland_law1_2014.pdf
    10. "Verordnung zur Änderung der Anlage des Neue-psychoaktive-Stoffe-Gesetzes und von Anlagen des Betäubungsmittelgesetzes" (PDF) (in German). Bundesanzeiger Verlag. Retrieved December 10, 2019.
    11. "Anlage NpSG" (in German). Bundesministerium der Justiz und für Verbraucherschutz. Retrieved December 10, 2019.
    12. "§ 4 NpSG" (in German). Bundesministerium der Justiz und für Verbraucherschutz. Retrieved December 10, 2019.
    13. Noteikumi par Latvijā kontrolējamajām narkotiskajām vielām, psihotropajām vielām un prekursoriem (Triptamīni) | http://likumi.lv/doc.php?id=121086
    14. http://www.legislation.govt.nz/act/public/1975/0116/latest/whole.html#DLM436576
    15. Misuse of Drugs Act 1971 (Legislation.gov.uk) | http://www.legislation.gov.uk/ukpga/1971/38/schedule/2/part/I/paragraph/3
    16. Misuse of Drugs Act 1971 (Legislation.gov.uk) |http://www.legislation.gov.uk/ukpga/1971/38/schedule/2/part/I#reference-M_F_c7632653-ddad-4420-f307-e3da1e36d30e
    17. The 2015 Florida Statutes - Title XLVI CRIMES - Chapter 893 - DRUG ABUSE PREVENTION AND CONTROL | http://www.leg.state.fl.us/Statutes/index.cfm?App_mode=Display_Statute&URL=0800-0899/0893/Sections/0893.03.html
    18. 5-MeO-MiPT Legal Status by Erowid | https://www.erowid.org/chemicals/5meo_mipt/5meo_mipt_law.shtml
    19. 2015 Minnesota Statutes | https://www.revisor.mn.gov/statutes/?id=152.02


    Information made possible with:

    1. PsychonautWiki is a community-driven online encyclopedia that aims to document the field of psychonautics in a comprehensive, scientifically-grounded manner.
    2. Erowid is a non-profit educational & harm-reduction resource with 60 thousand pages of online information about psychoactive drugs
    3. PubChem National Center for Bio Informatics
    4. Chemspider is a free chemical structure database providing fast access to over 34 million structures, properties and associated information.
    5. Wikipedia

    Additional APIs were used to construct this information. Thanks for ChemSpider, NCBI, PubChem etc.

    Data is constantly updated so please check back later to see if there is any more available information on this substance.